Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABI-008 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABI-008 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABI-008 | DRUG | nab-docetaxel |
Inclusion Criteria: Each subject must meet the following criteria to be enrolled in this study. 1. Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate that is clinically refractory to hormone therapy. 2. Zubrod Performance Status 0-1. 3. At the time of enrol...
ABI-008 is an investigational small molecule being studied for the treatment of hormone refractory prostate cancer, a form of prostate cancer that no longer responds to hormone therapy. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
The molecular target of ABI-008 has not been disclosed. It is a small molecule modality being investigated for its potential activity in hormone refractory prostate cancer. The specific biological pathway it acts on has not been publicly detailed.
ABI-008 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
ABI-008 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed, but the drug remains in early-stage clinical testing and is not yet available as a marketed therapy.
ABI-008 has been studied in one completed Phase 1 clinical trial, identified as NCT00477529. This trial enrolled 102 male patients with hormone refractory prostate cancer in the United States. The study was uncontrolled, meaning there was no comparator arm, and it was not randomized or double-blinded.
ABI-008 is not the same as abiraterone. Abiraterone is a different drug, marketed under brand names such as Zytiga, and is approved for prostate cancer. ABI-008 is a separate investigational compound with a distinct chemical identity, developed by Bristol-Myers Squibb.